Ulcerative colitis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• NLRP3 0
• NRF2 0
• STAT3 0
• JAK 2
• TNF 2
• IL-23 5
• MAPK 0
• PI3K 0
• TLR4 0
• AKT 0
• PPAR 0
• STING 0
• mTOR 0
• AMPK 0
• IL-6 0
• HIF-1 0
• TP53 0
• COX-2 0
• IL-17 0
• SIRT1 0
• CTNNB1 0
• GLP-1 0
• HMGB1 0
• HSP90 0
• IL-1 0
• CD40 0
• HDAC 1
• MMP-9 0
• GPX4 0
• JNK 0
• YAP 0
• EGFR 0
• CD19 3
• CTLA-4 0
• IL-4 0
• METTL3 0
• PARP 0
• VEGF 0
• BCMA 3
• ERK 0
• FOXP3 0
• MUC1 0
• PINK1 0
• ACE2 0
• G6PD 0
• IL-15 1
• KEAP1 0
• LRRK2 0
• MDM2 0
• PD-1 0
• PKM2 0
• TIGIT 0
• BRD4 0
• CCR5 0
• CD30 0
• EZH2 0
• IL-13 0
• MYC 0
• PD-L1 0
• PDE4 0

EU-13 is a filter, not a ranking: it only narrows the list.

20 of 20+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis

  NCT04469062· Eli Lilly and Company· Updated 6 May 2021

  “The trial was terminated secondary to a business decision, the original scientific question rendered moot by the external scientific community.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

  NCT06598943· Eli Lilly and Company· Source

• A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Eli Lilly and Company· Source

• COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)

  NCT07198113· University of North Carolina, Chapel Hill· Source

• Risankizumab for Fibrostenotic Crohn's Disease Treatment

  NCT07177118· First Affiliated Hospital of Wenzhou Medical University· Source

• An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Eli Lilly and Company· Source

• A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis

  NCT04469062· Eli Lilly and Company· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 25
• Organoids 15
• Mendelian Randomization Analysis 48
• Gene Expression Profiling 76
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 5
• Proteomics 29
• Metabolomics 48
• Mass Spectrometry 5
• Flow Cytometry 8
• Immunohistochemistry 18
• Magnetic Resonance Imaging 10
• Machine Learning 43
• Deep Learning 11
• Cohort Studies 89
• Genome-Wide Association Study 56

• A mucosal barrier injury related six gene transcriptomic signature associated with ulcerative colitis using machine learning and public transcriptomic data.

  PLoS One, Nov 2026

• Interpretable machine learning models for early prediction of Crohn's disease and ulcerative colitis in a nationwide health system.

  J Crohns Colitis, Oct 2026

• Integrated Multi-Omics, Machine Learning, and Single-Cell Analysis Provide Insights into Potential Multi-Target Candidate Mechanisms of Combined MAGL11 and Icaritin in Alleviating Imidazole Propionate-Driven Metabolic Intestinal Injury.

  Drug Des Devel Ther, Sept 2026

• Identification of Ferro-Aging-Related Biomarkers for Ulcerative Colitis Through Integrated Machine Learning, Single-Cell Analysis, and Spatial Transcriptomics.

  FASEB J, Sept 2026

• Multi-omics analysis identifies macrophage immunometabolic signatures in ulcerative colitis.

  Front Cell Infect Microbiol, Sept 2026

• Potential hazard assessment of 6PPD-quinone in the context of ulcerative colitis: network toxicology, machine learning, transcriptomic analysis, and preliminary In vivo validation.

  Front Immunol, Aug 2026

• Identification and validation of novel platelet-related genes in ulcerative colitis using bioinformatics and machine learning strategies.

  PeerJ, Aug 2026

• Machine learning-driven identification and experimental validation of key biomarkers in the bile acid metabolic pathway associated with ulcerative colitis.

  Front Immunol, Aug 2026

• PathMED: an R toolkit for single-sample molecular scoring and machine learning with omics data.

  Bioinformatics, Aug 2026

• Rapid fecal lipidome profiling in inflammatory bowel disease: A novel approach for exploratory disease molecular characterization and therapeutic monitoring.

  J Pharm Biomed Anal, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.